![]() |
Name |
7-chloro-3,4-dihydro-6,8-dihydroxy-3-methylisocoumarin
|
Molecular Formula | C10H9ClO4 | |
IUPAC Name* |
7-chloro-6,8-dihydroxy-3-methyl-3,4-dihydroisochromen-1-one
|
|
SMILES |
CC1Cc2cc(O)c(Cl)c(O)c2C(=O)O1
|
|
InChI |
InChI=1S/C10H9ClO4/c1-4-2-5-3-6(12)8(11)9(13)7(5)10(14)15-4/h3-4,12-13H,2H2,1H3/t4-/m1/s1
|
|
InChIKey |
DGSBLHFAZVSZGE-SCSAIBSYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 228.63 | ALogp: | 1.9 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.67 |
Caco-2 Permeability: | -4.831 | MDCK Permeability: | 0.00002440 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.003 |
30% Bioavailability (F30%): | 0.014 |
Blood-Brain-Barrier Penetration (BBB): | 0.282 | Plasma Protein Binding (PPB): | 97.46% |
Volume Distribution (VD): | 0.484 | Fu: | 2.19% |
CYP1A2-inhibitor: | 0.902 | CYP1A2-substrate: | 0.444 |
CYP2C19-inhibitor: | 0.061 | CYP2C19-substrate: | 0.101 |
CYP2C9-inhibitor: | 0.319 | CYP2C9-substrate: | 0.754 |
CYP2D6-inhibitor: | 0.636 | CYP2D6-substrate: | 0.284 |
CYP3A4-inhibitor: | 0.156 | CYP3A4-substrate: | 0.146 |
Clearance (CL): | 13.189 | Half-life (T1/2): | 0.74 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.146 |
Drug-inuced Liver Injury (DILI): | 0.902 | AMES Toxicity: | 0.036 |
Rat Oral Acute Toxicity: | 0.089 | Maximum Recommended Daily Dose: | 0.518 |
Skin Sensitization: | 0.445 | Carcinogencity: | 0.48 |
Eye Corrosion: | 0.013 | Eye Irritation: | 0.906 |
Respiratory Toxicity: | 0.734 |